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Regional Differences
Invalidate U.S. Sperm Trend
Conclusions
Regarding the continuing debate in EHP
over the question ofwhether or not human
sperm densities have declined in the
United States, I feel compelled to respond
to the statement bySwan et al. (1) that
regional variation would not be inconsistentwith
the average decline that we demonstrated in
Europe and the United States.
In referring to regional variation in sperm
densities, Swanetal. cite theworkofFisch et
al. (2) as indicating that sperm counts have
not declined in the United States. In this
study, sperm counts were analyzed in Los
Angeles, California; Roseville, Minnesota;
and New York, New York. A study by
MacLeod and Wang (3) indicates that
sperm counts have remained constant in
New York since 1938. In addition, two
other published studies report that sperm
counts have not dedined in Wisconsin (4)
or in Seattle, Washington (5). There is not a
single studyofhealthymen from anyfertility
center or sperm bank that has reported a
decline inspermcounts intheUnitedStates.
The regional variation in sperm counts,
with a nearly twofold difference in average
sperm counts between Los Angeles and
New York, invalidates any study that
attempts to demonstrate a twofold decline
in sperm counts based on trends over time
in reporting of sperm counts from differ-
ent regions of the United States (6).
Despite the assertion ofSwan et al. (7) that
the data are robust, there can be no valid
demonstration of a twofold decline in
sperm counts in the United States when
normal sperm counts vary nearly as much
between LosAngeles and NewYork.
John Heinze
JohnAdamsAssociates
Washington, D.C.
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On "Scents and Sensitivity"
I was delighted to learn ofthe informative
article, "Scents and Sensitivity" [EHP
106:A594-A599 (1998)]. I would like to
see this issue get the major media coverage
itwarrants.
Being extremely sensitive to fragrances,
I have been seeking accommodation for
over two years in the large office where I
work. I was recently granted a private
office space (without a door) and the firm
purchased an air cleaner (HEPA with car-
bon pre-filter) for myuse.
My employers' bottom line is that they
areunwilling to requestpeople toforego use
ofpersonal scented products in the office. I,
however, am unwilling to wear a face mask
all day in a work environment that would
not, by nature ofthe work being done here,
requireanyone towear amask.
Ifagovernment agencywere to publidy
recognize that there is a health risk to some
people from chemically based fragrances,
offices such as the one where I work would
be able to restrict use of scented personal
products. The health of people such as
myself would be greatly benefited and no
onewouldbe injuredbythe omission.
PeggyDavis
Atlanta, Georgia
Chiorpyrifos (Dursban) and
Dow Employees
Papers published in EHP concerning
adverse effects of pesticide exposure have
helped protect the public's health. These
include the study by Guillette et al. (1)
concerning learning impairment in young
children exposed to pesticides; the birth
defects-pesticides study by Garry et al. (2;
brain tumors in pesticide-exposed children
(3); and the studybyGurunathan et al. (4)
demonstrating volatilization and condensa-
tion ofDursban onto indoor surfaces, thus
potentiating exposure.
The artide by Gibson et al. (5) in the
June issue ofEHPraises a number oftrou-
bling questions. The authors failed to cite
the reasons for EPA restrictions on the use
of (chlorpyrifos) Dursban (6,7) and the
EPA report that reviewed thousands of
adverse reports to the EPAand poison con-
trol centers (8).
Gibson et al. (5) allege that chlorpyrifos
is notmutagenic. Ofthe28 Dursban toxicity
tests reported in the EPA database for 1996,
19 were negative for gene mutation, 3 were
positive for DNA damage, 1 was positive for
aneuploidy, and 2were positive for micronu-
cleus disruption (9). Genetic damage was
seen inapplicators ofpesticdes (10).
Gibson et al. (5) daim that chloripyrifos
is not teratogenic and does not adversely
affect reproduction. In November 1996,
under Section 6(a)(2) of the Federal
Insecticide, Fungicide, and Rodenticide Act
(FIFRA), DowElanco itself reported 12
adverse reproductive effects to the EPA as a
part of its late adverse reaction reports. A
yearlater, Dowreported athirteenthhuman
case and adverse reproductive outcome in a
breeder dog (11). The material safety data
sheetforDursbanTC (12) states,
Fetotoxicity and fetal development abnormalities
were observed in a chronic ingestion study of
pregnant mice, but the same dose produced severe
maternal toxicity.
Chlorpyrifos, the pesticidal agent in
Dursban, is both a chlorinated and
organophosphate chemical, with toxicity
characteristics of each class of chemicals.
The product Dursban is a complex mix-
ture, containing sulfotepp and trichloropy-
ridinol (TCP) in addition to chlorpyrifos.
TCP is used to manufacture chlorpyrifos,
is found in the commercial product, is the
metabolic breakdown product, and has
been reported to be teratogenic at doses
that are nontoxic to the mother (13,14).
Goldsmith et al. (15) reported birth
defect cases in Israel. These pesticide expo-
sures included Dursban, and were also
reported directly to the U.S. EPA (16). Still
Dow has been reluctant to accept the con-
cept that exposure to a chlorinated
organophosphate chemical designed to kill
insects by interfering with neurological
function could harm the developing
human. Whitney et al. (17) reported specif-
ic cellular mechanisms for developmental
neurotoxicity.
Gibson et al. (5) cited only four chil-
dren with birth defects [see Sherman (18)].
There actually were eight children with
birth defectswho had beenexposed in utero
to Dursban (15)). Discussing the findings,
Gibson et al. (5) daimed lackof"consisten-
cy of symptoms among the children."
Actually, the findings are not symptoms,
but actual defects, and there is astrong pat-
tern, calculated at odds of1045 for the first
fourchildren (20). Tabulation ofeight chil-
dren demonstrates a consistent pattern (see
Table 1). In keeping with standard scientif-
ic methodology, other causes of birth
defects have been explored (seeTable 2).
Gibson et al. (5) state that I said "the
mother's exposures to chlorpyrifos hap-
pened too late in the child's development
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to be toxicologically significant." My state-
ment was in response to a question from a
judge in regard to another child that was
not involved in the case under considera-
tion (21). Although I expressed concern
about testifying to facts in a case without
the records before me and without the
family being represented by their attorney,
I was required to answer the judge's hypo-
thetical questions. I testified (1,9) that the
child's defects
are the same pattern as the other seven
children.... [A]nd he [the child] follows
the same pattern of the boys in that all
boys had undescended testicles.
When I reviewed the actual records, the
record is clear: when the family home was
treated with Dursban, the unborn son was
an 11.5-week-old fetus. The child died at 7
years of age. His abnormalities, consistent
with the reported pattern, were confirmed
on autopsy. Thus, my testimony was not
accurately represented by Gibson et al. (5).
(Although I was paid to examine six ofthe
children and to review the medical records
of one child who subsequently died, I was
not compensated for reviewing the docu-
ments for two ofthe children.)
To say that any mother's exposures to
chlorpyrifos "happened too late in the
child's development to be toxicologically
significant" (5) would be inaccurate.
Throughout intrauterine life, the develop-
ing fetus undergoes rapid cell growth, pro-
grammed cell death (apoptosis), and cell
rearrangement, which are all time- and
space-dependent. Interference with any of
these processes results in abnormalities of
subsequent growth and development. The
specific disruption of intrauterine develop-
ment depends upon both the inciting
agent(s) and the state ofdevelopment ofthe
embryo, expressed subsequently as anatom-
ic and/or functional defects. Thus, exposure
later in fetal development or in infancy will
result in defects that differ from those pro-
duced earlier in development. One child
exposed to Dursban as an infant (22)
became essentially quadriplegic (21).
Wargo (23), the National Research Council
(24), and the Food Quality Protection Act
of 1996 agree on the special vulnerability of
children to pesticide exposures.
Gibson et al. (5) further state that
"Sherman's work does not adhere to general
scientific standards used in medical and
clinical practice." In the child's case cited by
Gibson et al., I examined the child; inter-
viewed the mother, father, and brother; vis-
ited theworkplace where the mother's expo-
sure occurred; visited the home ofthe child;
spoke with the treating physician; read all of
the child's and mother's medical records;
Table 1. Birth defects in children exposed in uteroto Dursban
Child
Defect 1 2 3 4 5 6 7 8
Sex of child Female Male Male Female Female Male Female Male
Brain defects
Structural deformities + + + + + + + +
Ventricular + + + + + + +
Microcephaly + + + - + +
Hydrocephaly + + 0 + + - +
Atrophyof brain - + + - + + +
Abnormality type CC CC SP DM CC CC
Eye defects
Structural Mi Mi,C Mi Cl + +
Blind + OT + 0 + LO 0 LO
Cataract + 0 + 0 + + 0 0
Facial
Palate abnormality + + + +,Cp + + + +
Cleftlip 0 0 0 + 0 0 CT +
Tooth abnormality + 0 + + + - + +
Nose abnormality + 0 0 + SM SM + +
Externalear + + 0 +D 0 0 + +
Other 7N AS AS RP
Heart - Hl H2 - U + - AS,D
Genital
Abnormal external + + + 0 + + U +
Specific abnormality F U U,P U,P U,P
Other
Mental retardation + + + N + + + +
Nipples wide-spread + 0 + + + + + +
Foot abnormalities + + + 0 +
Hypotonia + + + - + + +
Growth retardation + + + + + + - +
Abbreviations: N, normal; 0, defect not present; +, defect present;Cp, cleftpalate; CC, corpus callosum; SP, septum pel-
licudum; Mi, micro-ophthalmia; C, cyst of eye; Cl, cleft in eye; OT, optic tracts abnormal; D,totally deaf; F, fused labia; U,
undescended testes; P,microphallus; DM, demyelinization; CT, clefttongue; 7N, seventh cranial nerve palsy; AS, asym-
metry; Hl, atrial-septal defect and pulmonary stenosis; H2, right aortic arc; L0, low vision; SM, unusually small nose; RP,
paralysis on right side offace; -, defect not apparent, determination delayed until growth is achieved, and/orsurgical and
autopsyfindings.
Table 2. Review of medical history and chemical exposures
Child
Findings 1 2 3 4 5 6 7 8
Chromosome studies N N N N N N N N
Maternal smoking No No No No No No No No
Maternal alcohol use No No No A No No No No
Infections during pregnancy No PU No No No No No No
Pregnancy medication use T S T 0 Ty Ty Pr 0
Family history of birth defects
Child's mother 0 0 0 0 0 0 0,CB 0
Child's father 0 0 0 0 0 0 0,LD 0
Matgrandmother 0 0 0 0 0 0 0 0
Matgrandfather U 0 U 0 0 0 0 0
Patgrandmother 0 0 0 0 0 0 0 0
Patgrandmother 0 0 0 0 0 0 0 0
Birth defects in
othersiblings 0 0 0 0 0 0 0 0
Other chemical exposures
during pregnancy 0 C 0 F 0 0 Cy D/B
Dursban product used LO TC LO LO PU PU 270 Sp
Abbreviations: Mat, maternal; Pat, paternal; N, normal; 0, none; A, "a couple ofsips ofwine one time during pregnancy';
T, occasional Tylenol; S, occasional Sudafed, amoxicillin (1 course oftreatment); C, home previously treated with chlor-
dane ; F, firefog; U, unknown; Cy, cypermethrin; CB, craniostosis in brother's child; LD, learning disability in seizure in
past; Ty, "maybe a Tylenol; Pr, progesterone; Sp, Spectricide; D/B, diazinon/Bengal spray; PU, specific Dursban product
is unknown; LO,TC, PU, 270, and Sp are specific Dursban products.
and submitted over 10,000 pages of docu-
ments, which I rely on for my opinion. I
have also published other teratology reports
that link chemical exposureduring pregnan-
cy to birth defects (25).
Gibson et al. (5) cited the judge who
ruled against the family of one of the
Dursban-affected children assaying,
My tentative view is that Dr. Sherman's case
studies do nothing more scientifically than to
suggest a causal relation.
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That there is a causal relationship, based
upon human case finding, animal testing,
biochemistry, and structure-activity rela-
tionships, is precisely the point. This has also
been demonstrated by additional indepen-
dent physicians and scientists and appears in
various publications and court records.
The cost of caring for one of these
totally dependent children is in excess of
$500,000. The financial, emotional, social,
and physical burdens upon the families is
staggering. Prevention is imperative.
Janette D. Sherman
Alexandria, Virginia
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Response to Sherman
We find it unnecessary to address all state-
ments made by Janette Sherman in her let-
ter about our article in the June issue of
EHP (1). It is important to note that the
Centers for Disease Control and Prevention
(CDC), the U.S. EPA, and the California
EPA have each reviewed Sherman's argu-
ments and purported evidence and con-
cluded that Sherman has failed to establish
a legitimate association between human
exposure to chlorpyrifos and teratogenicity.
In a letter to Jerome Blondell of the U.S.
EPA (2), the CDC commented on
Sherman's evidence as follows:
At the present, there does not appear to be a con-
sistent phenotypic pattern of anomalies among
the infants whose records we reviewed. In addi-
tion, you reported that [chlorpyrifos] is used
extensively in the United States. Based on the
available medical records and the likely high fre-
quency ofthis exposure, we would be hesitant to
recommend pursuing major epidemiological
studies at this point in time.
Subsequently, on 14 January 1997,
Blondell issued a memorandum (3) which
stated that
HED [the Health Effects Division of the EPA]
concludes that available evidence does not sup-
port a finding of teratogenicity based on human
epidemiology studies and case reports.
Similarly, in a memorandum dated 27
January 1997 (4), R. Cochran, staff toxi-
cologist ofthe Medical Toxicology Branch
ofthe Department of Pesticide Regulation
ofthe California EPA stated
There was no scientific evidence presented in
either paper by Dr. Sherman which supported
the contention that chlorpyrifos could cause
birth defects-either in laboratory animals or
humans.
In addition to government scientists
and regulators, two independent panels of
scientific experts have comprehensivelx
reviewed published chlorpyrifos toxicology
and epidemiology studies, including
Sherman's papers, and both have rejected
the scientific validity of any claims associ-
ating chlorpyrifos exposure with birth
defects (5,6).
We stand behind our paper in all
respects, and we feel that any objective
review of the relevant data will strongly
support our conclusions.
James E. Gibson
Dow AgroSciences LLC
Indianapolis, Indiana
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